Announcement • Mar 17
Neuromeka Co., Ltd., Annual General Meeting, Mar 27, 2026 Neuromeka Co., Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 78, achasan-ro, seongdong-gu, seoul South Korea New Risk • Feb 04
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩22b free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 32% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (16% increase in shares outstanding). New Risk • Jan 13
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩22b free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 32% per year over the past 5 years. New Risk • Oct 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩33b free cash flow). Earnings have declined by 34% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (7.4% average weekly change). New Risk • May 30
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩41b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩41b free cash flow). Earnings have declined by 35% per year over the past 5 years. Announcement • Mar 26
Neuromeka Co., Ltd. announced that it has received KRW 5.000007554 billion in funding from DN Solutions Co., Ltd. On March 25, 2025, Neuromeka Co., Ltd. closed the transaction. Announcement • Mar 14
Neuromeka Co., Ltd., Annual General Meeting, Mar 28, 2025 Neuromeka Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: auditorium, 78, achasan-ro, seongdong-gu, seoul South Korea New Risk • Dec 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 37% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change). Announcement • Nov 30
Neuromeka Co., Ltd. announced that it expects to receive KRW 10 billion in funding Neuromeka Co., Ltd. announced a private placement to issue Zero Coupon Series 2 Bearer, Unsecured, Non-Guaranteed Convertible Bonds Due December 3, 2029 for the gross proceeds of KRW 10,000,000,000 on November 29, 2024. The transaction will include participation from new investor POSCO Holdings CVC 2 New Technology Investment Fund. The transaction has been approved by shareholders, restricted to a hold period, expected to close on December 3, 2024, 100% conertible into 417,868 shares at a fixed conversion price of KRW 23,931 from December 03, 2025 to November 3, 2029, bears zero coupon rate, 1% maturity rate and matures on December 3, 2029. New Risk • Jun 06
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩44b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. This is currently the only risk that has been identified for the company. Announcement • Sep 15
Neuromeka Participates in FABTECH 2023, Unveiling 3D Vision Collaborative Robot Welding Solution Neuromeka unveiled its collaborative robot welding solution during FABTECH 2023, North America's largest metal forming, fabricating, welding and finishing event. Hosted in Chicago at the McCormick Place Convention Center from September 11 to 14, 2023, this event brings together major companies from the metal processing, manufacturing, welding, and automation industries. The collaborative robot welding solution introduced by Neuromeka at this event is specifically tailored for block welding processes in the construction of large ships. It has features such as arc sensor-based welding seam tracking and automatic detection of welding irregularities using 3D cameras. In addition, the ship block and welding seam extraction results recognized by the 3D cameras are displayed in real-time on a smart touch pendant, enabling the easy creation of essential process programs for ship block welding with straightforward settings. Neuromeka's collaborative robot, 'Indy,' employed in this solution, incorporates an automatic stop mechanism upon collision with either individuals or its surroundings, ensuring safe coexistence with human operators in shared spaces. Its user-friendly interface and simplified programming capabilities cater to non-experts. This solution is expected to provide significant advancements to core industries, small and medium-sized enterprises, and the shipbuilding sector, which has been grappling with challenges posed by major disasters and labor shortages. In recent developments, Neuromeka obtained safety certification for special-purpose food processing equipment and related components from the National Sanitation Foundation (NSF) in the United States last month, further accelerating its entry into the North American F&B automation market. Announcement • Jul 06
Neuromeka Co.,Ltd. announced that it expects to receive KRW 40 billion in funding from NH Investment & Securities Co., Ltd. Neuromeka Co.,Ltd. announced a private placement of series 1 Bearer type non-interest-bearing non-guaranteed privately placed convertible bonds for proceeds of KRW 40,000,000,000 on July 4, 2023. the transaction will include participation from Daeshin-Skywalk New Technology Fund, DSC Home Run Fund 1, Orion Luxury KOSDAQ Venture General Private Equity Trust No. 72, Orion Luxury KOSDAQ Venture General Private Equity Trust No. 76 and Orion The banks 3 general private equity trust, the fund managed by NH Investment & Securities Co., Ltd. The bonds will bear zero interest rate and will mature on July 6, 2028. The bonds are 100% convertible into into 1,131,637 shares at an conversion price of KRW 35,347 per share. The bonds will start conversion from July 6, 2024 and will end on June 6, 2028. The transaction is expected to close on July 6, 2023. The transaction was approved by the board of directors of the company. Breakeven Date Change • Nov 16
Forecast to breakeven in 2023 The 2 analysts covering NeuromekaLtd expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of ₩2.10b in 2023. Average annual earnings growth of 152% is required to achieve expected profit on schedule. 
